CoChat

Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer

Open access
Goetz, Matthew P., Kalari, Krishna R., Suman, Vera J., Moyer, Ann M., Yu, Jia, Visscher, Daniel W., Dockter, Travis J., Vedell, Peter T., Sinnwell, Jason P., Tang, Xiaojia, Thompson, Kevin J., Barman, Poulami, Mahoney, Douglas W., Carlson, Erin, Hart, Steven N., Yin, Ping, Qin, Bo, Felten, Sara J., McLaughlin, Sarah A., Moreno-Aspitia, Alvaro, Copland, John A., Northfelt, Donald W., Gray, Richard J., Hunt, Katie, Conners, Amy, Sicotte, Hugues, Eckel-Passow, Jeanette E., Kocher, Jean-Pierre, Ingle, James N., Ellingson, Marissa S., McDonough, Michelle, Wieben, Eric D., Weinshilboum, Richard, Wang, Liewei, Boughey, Judy C. · 2017 · JNCI: Journal of the National Cancer Institute
Cited by 80

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background: Breast cancer patients with residual disease after neoadjuvant chemotherapy (NAC) have increased recurrence risk. Molecular characterization, knowledge of NAC response, and simultaneous generation of patient-derived xenografts (PDXs) may accelerate drug development. However, the feasibility of this approach is unknown. Methods: We conducted a prospective study of 140 breast cancer patients treated with NAC and performed tumor and germline sequencing and generated patient-derived xenografts (PDXs) using core needle biopsies. Chemotherapy response was assessed at surgery. Results: Recurrent "targetable" alterations were not enriched in patients without pathologic complete response (pCR); however, upregulation of steroid receptor signaling and lower pCR rates (16.7%, 1/6) were observed in triple-negative breast cancer (TNBC) patients with luminal androgen receptor (LAR) vs basal subtypes (60.0%, 21/35). Within TNBC, TP53 mutation frequency (75.6%, 31/41) did not differ comparing basal (74.3%, 26/35) and LAR (83.3%, 5/6); however, TP53 stop-gain mutations were more common in basal (22.9%, 8/35) vs LAR (0.0%, 0/6), which was confirmed in The Cancer Genome Atlas and British Columbia data sets. In luminal B tumors, Ki-67 responses were observed in tumors that harbored mutations conferring endocrine resistance ( p53, AKT, and IKBKE ). PDX take rate (27.4%, 31/113) varied according to tumor subtype, and in a patient with progression on NAC, sequencing data informed drug selection (olaparib) with in vivo antitumor activity observed in the primary and resistant (postchemotherapy) PDXs. Conclusions: In this study, we demonstrate the feasibility of tumor sequencing and PDX generation in the NAC setting. "Targetable" alterations were not enriched in chemotherapy-resistant tumors; however, prioritization of drug testing based on sequence data may accelerate drug development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djw306

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 80

Metadata

Authors
Goetz, M. P., Kalari, K. R., Suman, V. J., Moyer, A. M., Yu, J., Visscher, D. W., Dockter, T. J., Vedell, P. T., Sinnwell, J. P., Tang, X., Thompson, K. J., Barman, P., Mahoney, D. W., Carlson, E., Hart, S. N., Yin, P., Qin, B., Felten, S. J., McLaughlin, S. A., Moreno-Aspitia, A., Copland, J. A., Northfelt, D. W., Gray, R. J., Hunt, K., Conners, A., Sicotte, H., Eckel-Passow, J. E., Kocher, J.-P., Ingle, J. N., Ellingson, M. S., McDonough, M., Wieben, E. D., Weinshilboum, R., Wang, L., & Boughey, J. C.
Venue
JNCI: Journal of the National Cancer Institute
Published
2017-03-09
Volume
109
Issue
7
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2593920943
Cited by
80
References
4
FWCI
3.15
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. https://app.cochat.ai/papers/10.1093/jnci/djw306
The paper
Goetz, M. P., Kalari, K. R., Suman, V. J., Moyer, A. M., Yu, J., Visscher, D. W., Dockter, T. J., Vedell, P. T., Sinnwell, J. P., Tang, X., Thompson, K. J., Barman, P., Mahoney, D. W., Carlson, E., Hart, S. N., Yin, P., Qin, B., Felten, S. J., McLaughlin, S. A., . . . Boughey, J. C. (2017). Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djw306

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.